We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. Yet despite so much promise, progress isn’t certain. Our commitment to research and development is crucial to sustaining innovation and continuing its progress.
LATEST ARTICLES
How Intellectual Property Protections Spur Innovation
Strong IP protections are critical to safeguarding innovation within the biopharmaceutical industry.
3 Groundbreaking Innovations That Were First Approved in the United States
Breakthrough therapies are approved in America quickly, and this translates to hope for patients and families.
Why Washington Shouldn't Copy the Flawed Pricing Policies of Other Countries
America is the world's leading source of innovation. Let's keep it that way.
Washington is considering policy changes that could threaten innovation
New policy proposals in Washington threaten to hamstring investment in innovation and jeopardize breakthroughs.
Policy Solutions to Push Progress Forward
We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we must not take this progress for granted.
RELATED ARTICLES
4 Revolutionary Approaches Contributing to the Drop in Cancer Mortality Rate
Since peaking in 1991, the death rate associated with cancer declined by 29%, which translates to 2.9 million fewer cancer deaths.
The Next Threat: Combatting Antimicrobial Resistance
After decades of helping to lower the mortality rate from pneumonia, tuberculosis and other types of infection, the medicines we rely on now face the growing threat of antimicrobial resistance.
World TB Day: How American Innovation Extends Around the World
One fourth of the global population has tuberculosis. American innovation is changing that.
HUBweek 2018: Why Innovation Needs Cross-Sector Collaboration
Innovation does not happen in a vacuum. Instead, it requires a rich ecosystem of talent, capital, expertise and logistics to translate theoretical science into life-saving treatments and therapies.
Innovation is Fragile, But Worth Protecting
The Atlantic, in partnership with PhRMA's GOBOLDLY campaign, convened thought leaders to discuss the policies needed to foster biopharmaceutical innovation while ensuring access and affordability for patients.
Achieving Innovation and Access Together
In today's new era of medicine, breakthrough treatments are revolutionizing how we fight disease, providing hope to patient populations that 20 years ago could never have dreamed of using the word "cure" when talking about their conditions.
Researcher Profile: Jirong Lu
Dr. Jirong Lu, a distinguished research fellow at Eli Lilly and Company (Lilly), traces the beginnings of her career to a high school fascination with chemistry.
How the New Era of Medicine is Disrupting Health Care
We are on the cusp of a major, positive disruption in the U.S. health care system due in part to the exponential growth in clinical data, advent and incorporation of artificial intelligence and the increasing realignment of the health care sector.
Change on the Horizon: The Future of Cancer Treatment
Experts and thought leaders touching every aspect of cancer came together for "Future Shapers: A New Era in Cancer Care", a conversation led by Axios and part of PhRMA's GoBoldly Campaign.
A Critical Quest: Working Toward Better Treatments for Brain Cancer
Glioblastoma is the most aggressive form of brain cancer, and one that impacts more than 12,000 Americans each year.
Researcher Profile: Dan Skovronsky
A neuroscientist and neuropathologist by training, Dan is responsible for development across all of Lilly's products - from clinical trials through approvals - specifically working within the areas of oncology, diabetes, Alzheimer's disease, immunology and pain management.
On the Front Lines of Science
In recent years, medical breakthroughs including new drug therapies and early disease monitoring technologies have accelerated rapidly. This has created wide-ranging transformations in patient care.
Cumulative Steps, Big Gains for Patients
Advances in treating debilitating diseases are often not the result of one single breakthrough, but rather an accumulation of knowledge and research over time.
Brain Cancer: Research Brings Hope to a Difficult Disease
Between 1998 and 2014, there were 75 unsuccessful drugs and 3 approved drugs for brain cancer.
